MAB Discovery expands 2013 partnership with BioNTech AG
German MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
European biotech stocks: New wave of optimism
In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November 6.
NousCom raises €42m
Swiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and Versant Ventures.
Blocking antibody recycling vs autoimmune diseases
Researchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular recycling process can remove autoantibodies from the blood of people with autoimmune diseases.
Another death related to allogenic CAR-T cell therapy
Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SAs allogenic CAR-T therapies. Preliminary results from two trials in CD19+ relapsed or refractory B-Cell acute lymphoblastic leukemia patients dosed with UCART19 suggest that cytokine release syndrome (CRS) associated with allogenic CAR-Ts must be managed very carefully.
BioGeneration Ventures Fund III closed at €82m
Dutch venture capital company BioGeneration Ventures (BGV) has closed its third fund, BGV III, at €82m exceeding the original target by €32m.
Ablynx raises US$230m
Belgian nanobody producer Ablynx closes an initial public offering of American Depositary Shares at Nasdaq totalling US$200m plus a fully exercised greenshoe option amounting aggregate gross proceeds to US$230.
CPHI Worldwide expands outreach
The worlds largest event for pharma professionals, CPHI worldwide, will see an expansion to the rapidly-growing field of biologics next year in Madrid
Insight into biomarkers
AYOXXAs LUNARIS platform:?In a case study "Translational proteomics: a new perspective for
ophthalmology research, Ayoxxa gives insights into the capabilities of its Lunaris multiplex protein
analysis platform.
300 jobs more: US company expands its Irish campus
US biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (€85m) expansion plan for the company’s campus there.